NO780226L - Nye prostaglandin-analoge og fremgangsmaate til deres fremstilling - Google Patents

Nye prostaglandin-analoge og fremgangsmaate til deres fremstilling

Info

Publication number: NO780226L
Authority: NO; Norway
Prior art keywords: compound; formula; atoms; residue; branched
Prior art date: 1977-01-21

Application number

NO780226A

Other languages

English (en)

Norwegian (no)

Inventor

Wilhelm Bartmann

Gerhard Beck

Ulrich Lerch

Herman Teufel

Bernward Schoelkens

Original Assignee

Hoechst Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-01-21

Filing date

1978-01-20

Publication date

1978-07-24

1978-01-20 Application filed by Hoechst Ag filed Critical Hoechst Ag

1978-07-24 Publication of NO780226L publication Critical patent/NO780226L/no

Links

238000000034 method Methods 0.000 title claims description 10
238000002360 preparation method Methods 0.000 title description 5
150000003180 prostaglandins Chemical class 0.000 title description 3
150000001875 compounds Chemical class 0.000 claims description 24
125000004432 carbon atom Chemical group C* 0.000 claims description 15
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 12
150000002148 esters Chemical class 0.000 claims description 10
238000006243 chemical reaction Methods 0.000 claims description 9
-1 ethylene thioglycol acetals Chemical class 0.000 claims description 9
125000000217 alkyl group Chemical group 0.000 claims description 7
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
150000003839 salts Chemical class 0.000 claims description 7
239000001257 hydrogen Substances 0.000 claims description 5
229910052739 hydrogen Inorganic materials 0.000 claims description 5
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
229920006395 saturated elastomer Polymers 0.000 claims description 5
239000003795 chemical substances by application Substances 0.000 claims description 4
239000002253 acid Substances 0.000 claims description 3
150000001298 alcohols Chemical class 0.000 claims description 3
125000004181 carboxyalkyl group Chemical group 0.000 claims description 3
125000002768 hydroxyalkyl group Chemical group 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
150000002923 oximes Chemical class 0.000 claims description 3
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
239000005977 Ethylene Substances 0.000 claims description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
125000001931 aliphatic group Chemical group 0.000 claims description 2
150000001338 aliphatic hydrocarbons Chemical group 0.000 claims description 2
125000003545 alkoxy group Chemical group 0.000 claims description 2
125000002947 alkylene group Chemical group 0.000 claims description 2
125000003118 aryl group Chemical group 0.000 claims description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
125000005843 halogen group Chemical group 0.000 claims description 2
150000007529 inorganic bases Chemical class 0.000 claims description 2
229910052740 iodine Inorganic materials 0.000 claims description 2
150000007530 organic bases Chemical class 0.000 claims description 2
125000005188 oxoalkyl group Chemical group 0.000 claims description 2
239000001301 oxygen Substances 0.000 claims description 2
229910052760 oxygen Inorganic materials 0.000 claims description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
229940126601 medicinal product Drugs 0.000 claims 2
206010020772 Hypertension Diseases 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
229960000583 acetic acid Drugs 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
235000019439 ethyl acetate Nutrition 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
239000012362 glacial acetic acid Substances 0.000 description 3
239000000741 silica gel Substances 0.000 description 3
229910002027 silica gel Inorganic materials 0.000 description 3
239000000243 solution Substances 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
239000000010 aprotic solvent Substances 0.000 description 2
150000001735 carboxylic acids Chemical class 0.000 description 2
239000003480 eluent Substances 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
229940094443 oxytocics prostaglandins Drugs 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
IFFPICMESYHZPQ-UHFFFAOYSA-N Prenylamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCNC(C)CC1=CC=CC=C1 IFFPICMESYHZPQ-UHFFFAOYSA-N 0.000 description 1
LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
235000019486 Sunflower oil Nutrition 0.000 description 1
JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
150000001241 acetals Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
CJCSPKMFHVPWAR-JTQLQIEISA-N alpha-methyl-L-dopa Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 description 1
230000003288 anthiarrhythmic effect Effects 0.000 description 1
230000003178 anti-diabetic effect Effects 0.000 description 1
230000001741 anti-phlogistic effect Effects 0.000 description 1
239000003416 antiarrhythmic agent Substances 0.000 description 1
229940006138 antiglaucoma drug and miotics prostaglandin analogues Drugs 0.000 description 1
239000003524 antilipemic agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000004531 blood pressure lowering effect Effects 0.000 description 1
230000003182 bronchodilatating effect Effects 0.000 description 1
KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 1
229960005003 carbocromen Drugs 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
229960004782 chlordiazepoxide Drugs 0.000 description 1
ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000003026 cod liver oil Substances 0.000 description 1
235000012716 cod liver oil Nutrition 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
239000003218 coronary vasodilator agent Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
229960003529 diazepam Drugs 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
IPZJQDSFZGZEOY-UHFFFAOYSA-N dimethylmethylene Chemical compound C[C]C IPZJQDSFZGZEOY-UHFFFAOYSA-N 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
229960004580 glibenclamide Drugs 0.000 description 1
ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 description 1
229960004440 glymidine Drugs 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
150000002561 ketenes Chemical class 0.000 description 1
125000000468 ketone group Chemical group 0.000 description 1
230000003529 luteolytic effect Effects 0.000 description 1
229960004815 meprobamate Drugs 0.000 description 1
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
229960003105 metformin Drugs 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
239000000203 mixture Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
125000004043 oxo group Chemical group O=* 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
229960003243 phenformin Drugs 0.000 description 1
ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
229920000570 polyether Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
229960001989 prenylamine Drugs 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
239000002089 prostaglandin antagonist Substances 0.000 description 1
230000002997 prostaglandinlike Effects 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
229960003147 reserpine Drugs 0.000 description 1
MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000017550 sodium carbonate Nutrition 0.000 description 1
230000003033 spasmogenic effect Effects 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
239000002600 sunflower oil Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
229960005371 tolbutamide Drugs 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Furan Compounds (AREA)

NO780226A 1977-01-21 1978-01-20 Nye prostaglandin-analoge og fremgangsmaate til deres fremstilling NO780226L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19772702368 DE2702368A1 (de)	1977-01-21	1977-01-21	Neue prostaglandin-analoge und verfahren zu ihrer herstellung

Publications (1)

Publication Number	Publication Date
NO780226L true NO780226L (no)	1978-07-24

Family

ID=5999194

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO780226A NO780226L (no)	1977-01-21	1978-01-20	Nye prostaglandin-analoge og fremgangsmaate til deres fremstilling

Country Status (14)

Country	Link
JP (1)	JPS5392742A (fr)
AU (1)	AU3256178A (fr)
BE (1)	BE863206R (fr)
DE (1)	DE2702368A1 (fr)
DK (1)	DK29378A (fr)
ES (1)	ES466005A2 (fr)
FI (1)	FI780169A7 (fr)
FR (1)	FR2378008A2 (fr)
GB (1)	GB1577991A (fr)
LU (1)	LU78916A1 (fr)
NL (1)	NL7714520A (fr)
NO (1)	NO780226L (fr)
SE (1)	SE7800689L (fr)
ZA (1)	ZA78368B (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4094899A (en) *	1972-06-02	1978-06-13	Pfizer Inc.	Oxaprostaglandins
GB1545633A (en) *	1975-02-24	1979-05-10	American Cyanamid Co	11-deoxy substituted prostaglandins of the e and f series

1977
- 1977-01-21 DE DE19772702368 patent/DE2702368A1/de active Pending
- 1977-12-29 NL NL7714520A patent/NL7714520A/xx not_active Application Discontinuation
1978
- 1978-01-16 ES ES466005A patent/ES466005A2/es not_active Expired
- 1978-01-19 LU LU78916A patent/LU78916A1/de unknown
- 1978-01-19 FI FI780169A patent/FI780169A7/fi not_active Application Discontinuation
- 1978-01-19 AU AU32561/78A patent/AU3256178A/en active Pending
- 1978-01-19 SE SE7800689A patent/SE7800689L/xx unknown
- 1978-01-20 ZA ZA00780368A patent/ZA78368B/xx unknown
- 1978-01-20 DK DK29378A patent/DK29378A/da not_active Application Discontinuation
- 1978-01-20 NO NO780226A patent/NO780226L/no unknown
- 1978-01-20 JP JP573278A patent/JPS5392742A/ja active Pending
- 1978-01-23 BE BE184546A patent/BE863206R/fr not_active IP Right Cessation
- 1978-01-23 FR FR7801789A patent/FR2378008A2/fr active Pending
- 1978-01-23 GB GB2609/78A patent/GB1577991A/en not_active Expired

Also Published As

Publication number	Publication date
DK29378A (da)	1978-07-22
GB1577991A (en)	1980-10-29
FI780169A7 (fi)	1978-07-22
ES466005A2 (es)	1978-10-01
NL7714520A (nl)	1978-07-25
BE863206R (fr)	1978-07-24
DE2702368A1 (de)	1978-08-03
AU3256178A (en)	1979-07-26
JPS5392742A (en)	1978-08-15
FR2378008A2 (fr)	1978-08-18
SE7800689L (sv)	1978-07-22
ZA78368B (en)	1979-01-31
LU78916A1 (de)	1978-09-28

Publication	Publication Date	Title
KR100526282B1 (ko)	2006-05-17	디플루오로프로스타글란딘유도체및그의용도
HU188840B (en)	1986-05-28	Process for preparing glycerine derivatives and pharmaceutical compositions containing such compounds as active substances
US7674921B2 (en)	2010-03-09	Internal 1,15-lactones of fluprostenol and related prostaglandin F2α analogs and their use in the treatment of glaucoma and intraocular hypertension
NO155537B (no)	1987-01-05	Analogifremgangsmaate ved fremstilling av terapeutisk aktive, nye carbacycliner.
FR2517302A1 (fr)	1983-06-03	Esters et amides de 13 14-bisdehydroprostaglandines
HU183263B (en)	1984-04-28	Process for preparing 9-chloro-prostaglandin derivatives
US3781306A (en)	1973-12-25	Bicyclic lactone diformate
JPH09501943A (ja)	1997-02-25	新規９−クロル−プロスタグランジン−誘導体
WO1998000389A1 (fr)	1998-01-08	Derive d'acide 2-hydroxypropionique et son procede de fabrication
JPS6021979B2 (ja)	1985-05-30	４，４，５，５―テトラデヒドロｐｇｅ↓１
DK163579B (da)	1992-03-16	Analogifremgangsmaade til fremstilling af carbacyklinderivater
US4088775A (en)	1978-05-09	15-Ethylenedioxy-prostanoic acid derivatives and esters thereof and intermediates thereof
US3475408A (en)	1969-10-28	N(6) alkenyl 5-substituted adenosine
AU2001233286A1 (en)	2001-10-25	Internal 1,15-lactones of fluprostenol and related prostaglandin F2alpha analogs and their use in the treatment of glaucoma and intraocular hypertension
JPH0352465B2 (fr)	1991-08-12
NO832414L (no)	1984-01-03	Fremgangsmaate ved fremstilling av nye carbacyclinamider
EP0124379B1 (fr)	1986-08-13	Dérivés d'hydroquinone et procédé pour leur production
IE45010B1 (en)	1982-06-02	A phenolic ester of p-isobutylhydratropic acid, its preparation and use
HU191110B (en)	1987-01-28	Process for the production of the 15-cycloaliphatic derivatives 13,14-didehydro-carbaprostacyclines
US4251669A (en)	1981-02-17	Analogues of prostanoic acids
GB1577991A (en)	1980-10-29	Analogues of prost-5,10,138-trienoic acid and process for preparing them
IL44837A (en)	1977-11-30	Trialcaoxybenzoylamino acids - carboxyls containing sulfur, their preparation and distillates containing them
JPH0222071B2 (fr)	1990-05-17
DE2702370C2 (de)	1987-03-26	Prostaglandin-Analoge, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
IL32073A (en)	1973-06-29	15(r)-prostanoic acid derivatives